Intercept Pharmaceuticals (NASDAQ: ICPT)
Some price data may be temporarily unavailable.
Intercept Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intercept Pharmaceuticals Company Info
Intercept Pharmaceuticals, Inc.
News & Analysis
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.
Why Intercept Pharmaceuticals Stock Plunged Today
A modest revenue miss sparked a sell-off in the liver disease company's shares today.
Why Intercept Pharmaceuticals Stock Is Soaring Today
Investors are cheering the drugmaker's Q3 update.
Nike's Down, but These 2 Nasdaq Stocks Fell Even Further Friday
Poor earnings and a business setback were costly for these companies.
Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021
The biotech can't seem to catch a break.
Are These the Next Meme Stocks?
Reddit's retail investors may soon be swooning over this under-the-radar trio of heavily short-sold companies.
With Important Trial Results Due in June, Is This Drugmaker a Good Buy Now?
The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?
Why Investors Loved Intercept Pharmaceuticals' Q3 Update
The company's quarterly results were fine, but the more important news from the biopharmaceutical wasn't financial.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.